October 16, 2020
Theratechnologies Appoints Two New Board Members
Montreal, Canada – October 16, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Andrew Molson and Mr. Alain Trudeau as new independent members to its Board of Directors.
“Both Andrew and Alain bring tremendous value to our Board. They are well-recognized and respected by their peers in the business community for their knowledge, expertise and vision,” said Ms. Dawn Svoronos, Chair of the Board, Theratechnologies Inc.
“On behalf of the Board of Directors at Theratechnologies, it is my pleasure to welcome them. We look forward to the important contribution Andrew and Alain will make as Theratechnologies enters a new chapter in its history. Theratechnologies recently announced its intent to develop tesamorelin for the treatment of Nonalcoholic Steatohepatitis (NASH) in the general population while it continues to advance its SORT1+ TechnologyTM platform in oncology. These programs, along with the commercialization of EGRIFTA SV® and Trogarzo®, position Theratechnologies to become a much larger player in the pharmaceutical industry,” added Ms. Svoronos.